Search

Your search keyword '"Marseglia, G."' showing total 2 results
Start Over Author "Marseglia, G." Topic immunization Journal italian journal of pediatrics
2 results on '"Marseglia, G."'

1. Pediatric health care professionals' vaccine knowledge, awareness and attitude: a survey within the Italian Society of Pediatric Allergy and Immunology.

Author

Del Duca, Elisabetta, Chini, Loredana, Graziani, Simona, Sgrulletti, Mayla, Moschese, Viviana, with the Italian Pediatric Immunology and Allergology Society (SIAIP) Vaccine Committee, Moschese, V., Chini, L., Sgrulletti, M., Dellepiane, R. M., Martire, B., Sangerardi, M., Montin, D., Ottaviano, G., Rizzo, C., Duse, M., and Marseglia, G.

Subjects
VACCINATION, INFLUENZA vaccines, PROFESSIONS, IMMUNIZATION, CONFIDENCE, ATTITUDE (Psychology), MEDICAL personnel, PEDIATRICS, PNEUMOCOCCAL vaccines, QUESTIONNAIRES, PEDIATRIC nursing, DESCRIPTIVE statistics, ROTAVIRUS vaccines, HERPES zoster vaccines, NURSE practitioners
Abstract

Background: Physicians play a key role in driving vaccine acceptance and their recommendations are crucial to address vaccine hesitancy. The aim of the study was to assess knowledge, awareness and attitude of Italian Pediatric Health Care Professionals (pHCPs) on vaccinations. Methods: An anonymous on-line questionnaire was developed within the Vaccine Committee of Italian Society of Pediatric Allergy and Immunology (SIAIP) and spontaneously completed by 231 Pediatricians and Pediatric Nurses (PN). Results: An accurate vaccine education was reported by 70% of pediatricians and 13% of PN but 11% of pediatricians versus 26% of PN consult social media instead of scientific sources for their vaccine update. The investigation on the pHCPs attitudes to vaccination in a personal and family setting highlights poor adherence to vaccinations. Only 63% of pediatricians versus 16% of PN (p < 0.0001) annually received the Flu vaccine. In their family setting 93% of pediatricians versus 51% of PN recommended all vaccinations (p < 0.0001). Anti-flu, anti-rotavirus, anti-zoster and anti-pneumococcal vaccines were not regularly recommended by all pHCPs due to doubts of uselessness (55% of pediatricians versus 40% of PN) and preference for "natural immunity" (44% of pediatricians versus 40% of PN). Conclusions: Our results indicate that pHCPs' attitude and confidence in regards to vaccines remain suboptimal. Current COVID-19 pandemic and the rapid development of vaccines could increase vaccine hesitancy. Due to the documented pHCPs' influence in the parental decision, educational interventions are needed to improve their level of knowledge and counselling skills in order to address parental vaccine hesitancy and to maintain continuity of immunization services. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

2. Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian Society of Neonatology

Author

Fabio Mosca, Mauro Calvani, Domenico Minasi, Chiara Petrolini, Carlo Caffarelli, Carlo Pietrasanta, Elena Chiappini, Arabella Martelli, Lorenza Pugni, Marzia Duse, G B Pajno, Mariangela Tosca, Sara Manti, Gian Luigi Marseglia, Fabio Cardinale, M. Miraglia Del Giudice, Amelia Licari, Chiappini, E., Petrolini, C., Caffarelli, C., Calvani, M., Cardinale, F., Duse, M., Licari, A., Manti, S., Martelli, A., Minasi, D., Miraglia Del Giudice, M., Pajno, G. B., Pietrasanta, C., Pugni, L., Tosca, M. A., Mosca, F., and Marseglia, G. L.

Subjects
Pediatrics, medicine.medical_specialty, Vaccination schedule, Hexavalent vaccines, Preterm infants, Vaccines, Review, 03 medical and health sciences, 0302 clinical medicine, 030225 pediatrics, Humans, Medicine, Age Factor, Hexavalent vaccine, Vaccines, Combined, 030212 general & internal medicine, Neonatology, Adverse effect, Immunization Schedule, Age Factors, Infant, Infant, Newborn, Infant, Premature, Italy, Practice Guidelines as Topic, business.industry, Tetanus, Diphtheria, lcsh:RJ1-570, lcsh:Pediatrics, medicine.disease, Vaccination, Immunization, Preterm infant, Vaccine-preventable diseases, business, Vaccine, Human
Abstract

Hexavalent vaccines, protecting against six diseases (diphtheria, tetanus, pertussis [DTaP], poliovirus, hepatitis B virus [HBV], and Haemophilus influenzae type b [Hib], are routinely the standard of care in Europe. The use of combined vaccines allows the reduction of number of injections and side effects, the reduction of costs, and the increase in adherence of the family to the vaccination schedule both in terms of the number of doses and timing. The safety profile, efficacy and effectiveness of hexavalent vaccines have been extensively documented in infants and children born at term, and data are accumulating in preterm infants. Hexavalent vaccines are particularly important for preterm infants, who are at increased risk for severe forms of vaccine preventable diseases. However, immunization delay has been commonly reported in this age group. All the three hexavalent vaccines currently marketed in Italy can be used in preterm infants, and recent data confirm that hexavalent vaccines have a similar or lower incidence of adverse events in preterm compared to full-term infants; this is likely due to a weaker immune system response and reduced ability to induce an inflammatory response in preterm infants. Apnoea episodes are the adverse events that can occur in the most severe preterm infants and / or with history of respiratory distress. The risk of apnoea after vaccination seems to be related to a lower gestational age and a lower birth weight, supporting the hypothesis that it represents an unspecific response of the preterm infant to different procedures. High seroprotection rates have been reported in preterm infants vaccinated with hexavalent vaccine. However, a lower gestational age seems to be associated with lower antibody titres against some vaccine antigens (e.g. HBV, Hib, poliovirus serotype 1, and pertussis), regardless of the type of hexavalent vaccine used. Waiting for large effectiveness studies, hexavalent vaccines should be administered in preterm infants according to the same schedule recommended for infants born at term, considering their chronological age and providing an adequate monitoring for cardio-respiratory events in the 48–72 h after vaccination, especially for infants at risk of recurrence of apnoea.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results